EWTX
Edgewise Therapeutics, Inc.
$32.70
+0.01
(+0.03%)
Mkt Cap
3.52B
Volume
499,686
52W Range
12.15-39.96
Sector
Healthcare
Beta
0.25
EPS (TTM)
-1.66
P/E Ratio
-15.23
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (167.79M) | (133.81M) | (100.16M) | (67.64M) | (42.81M) | (17.05M) | (9.49M) |
| EPS | -1.63 | -1.45 | -1.57 | -1.26 | -0.86 | -0.35 | -0.19 |
| Free Cash Flow | (143.82M) | (110.34M) | (97.69M) | (58.18M) | (34.17M) | (14.84M) | (9.35M) |
| FCF / Share | -1.40 | -1.19 | -1.53 | -1.09 | -0.69 | -0.30 | -0.19 |
| Operating CF | (143.82M) | (109.03M) | (91.95M) | (52.63M) | (33.51M) | (14.63M) | (9.17M) |
| Total Assets | 552.60M | 486.82M | 340.04M | 367.10M | 285.23M | 131.14M | 24.54M |
| Total Debt | 3.99M | 4.74M | 5.41M | 4.41M | 0 | 160.21M | 0 |
| Cash & Equiv | 61.15M | 41.67M | 86.10M | 21.99M | 15.57M | 104.92M | 23.65M |
| Book Value | 522.26M | 459.22M | 318.83M | 346.72M | 274.38M | (33.42M) | (16.85M) |
| Return on Equity | -0.32 | -0.29 | -0.31 | -0.20 | -0.16 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (49.01M) | (50.22M) | (40.67M) | (36.12M) | (40.80M) | (39.66M) | (34.13M) | (31.50M) | (28.52M) | (30.14M) | (25.71M) | (21.47M) |
| EPS | -0.46 | -0.47 | -0.39 | -0.34 | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 | -0.47 | -0.41 | -0.34 |
| Free Cash Flow | (42.80M) | (38.41M) | (34.87M) | (32.63M) | (37.91M) | (27.23M) | (27.89M) | (26.32M) | (28.89M) | (26.99M) | (22.52M) | (20.99M) |
| FCF / Share | -0.40 | -0.37 | -0.33 | -0.31 | -0.40 | -0.29 | -0.30 | -0.28 | -0.33 | -0.42 | -0.35 | -0.33 |
| Operating CF | (42.54M) | (38.59M) | (34.78M) | (32.58M) | (37.87M) | (26.96M) | (27.37M) | (26.10M) | (28.60M) | (26.83M) | (22.06M) | (20.23M) |
| Total Assets | 518.52M | 552.60M | 583.47M | 613.33M | 454.39M | 486.82M | 511.28M | 531.65M | 553.81M | 340.04M | 311.36M | 330.62M |
| Total Debt | 3.79M | 3.99M | 4.18M | 4.37M | 4.56M | 4.74M | 4.44M | 4.99M | 5.25M | 5.41M | 5.53M | 5.64M |
| Cash & Equiv | 33.21M | 61.15M | 46.00M | 43.40M | 49.92M | 41.67M | 44.81M | 43.48M | 30.26M | 86.10M | 32.96M | 31.81M |
| Book Value | 493.20M | 522.26M | 558.65M | 589.07M | 429.72M | 459.22M | 488.88M | 510.47M | 534.94M | 318.83M | 290.43M | 311.45M |
| Return on Equity | -0.10 | -0.10 | -0.07 | -0.06 | -0.09 | -0.09 | -0.07 | -0.06 | -0.05 | -0.09 | -0.09 | -0.07 |
EWTX News
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Contrasting ABVC BioPharma (NASDAQ:ABVC) and Edgewise Therapeutics (NASDAQ:EWTX)
Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 12-Month High – Should You Buy?
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of “Moderate Buy” by Analysts
SG Americas Securities LLC Buys 78,842 Shares of Edgewise Therapeutics, Inc. $EWTX
Edgewise Therapeutics (NASDAQ:EWTX) CMO Joanne Donovan Sells 28,662 Shares
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Why Edgewise Therapeutics Stock Topped the Market on Tuesday